A detailed history of Quantbot Technologies LP transactions in Insmed Inc stock. As of the latest transaction made, Quantbot Technologies LP holds 1,827 shares of INSM stock, worth $127,890. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,827
Holding current value
$127,890
% of portfolio
0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$62.0 - $79.01 $113,274 - $144,351
1,827 New
1,827 $133,000
Q3 2023

Nov 07, 2023

BUY
$19.86 - $26.93 $591,828 - $802,514
29,800 New
29,800 $752,000
Q3 2022

Nov 07, 2022

SELL
$20.88 - $28.21 $44,933 - $60,707
-2,152 Reduced 87.77%
300 $6,000
Q2 2022

Aug 09, 2022

BUY
$17.07 - $25.71 $40,012 - $60,264
2,344 Added 2170.37%
2,452 $48,000
Q1 2022

May 16, 2022

SELL
$20.42 - $28.13 $16,050 - $22,110
-786 Reduced 87.92%
108 $2,000
Q4 2021

Feb 11, 2022

BUY
$25.89 - $33.45 $23,145 - $29,904
894 New
894 $24,000
Q4 2020

Feb 12, 2021

SELL
$31.45 - $40.54 $48,244 - $62,188
-1,534 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$26.0 - $34.5 $39,884 - $52,923
1,534 New
1,534 $49,000
Q2 2020

Aug 13, 2020

SELL
$14.11 - $29.42 $3,950 - $8,237
-280 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$13.63 - $33.98 $3,816 - $9,514
280 New
280 $4,000
Q3 2019

Nov 12, 2019

SELL
$15.49 - $25.78 $96,038 - $159,836
-6,200 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$23.0 - $32.19 $142,600 - $199,578
6,200 New
6,200 $158,000
Q2 2018

Aug 13, 2018

SELL
$20.0 - $29.72 $96,820 - $143,874
-4,841 Closed
0 $0
Q1 2018

May 11, 2018

BUY
$21.69 - $32.99 $69,538 - $105,765
3,206 Added 196.09%
4,841 $109,000
Q4 2017

Feb 12, 2018

SELL
$26.43 - $31.78 $28,729 - $34,544
-1,087 Reduced 39.93%
1,635 $50,000
Q3 2017

Nov 07, 2017

BUY
$11.61 - $31.21 $31,602 - $84,953
2,722
2,722 $84,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.48B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.